ARDT Ardent Health, Inc. Insider Trading

Director Robert Demichiei buys 11,260 shares of ARDT at $8.73, raising holdings to 35,564 shares; stock down -44.2% from 52-week high.

Director Robert Demichiei purchased 11,260 shares at $8.73 on 2026-06-05, increasing his shareholding by 46.3% from 24,304 to 35,564 shares for a total investment of $98,299.80. The purchase occurs with the stock trading at $8.64, down -44.2% from its 52-week high of $15.48 and down -14.5% over the past 30 days. Ardent Health trades at a P/E of 9.19 with positive fundamentals including $1.6B in quarterly revenue, $39.8M in net income, and 6.0% annual revenue growth, suggesting the depressed price may reflect market sentiment rather than deteriorating business performance. The substantial increase in Demichiei's ownership stake warrants tracking to establish whether this represents a broader pattern of insider accumulation at current valuations.

CFO Alfred Lumsdaine buys 10,000 shares of ARDT at $8.81 as stock down -44.2% from 52-week high

Alfred Lumsdaine, Chief Financial Officer, purchased 10,000 shares at $8.81 on 2026-06-05, expanding his holdings to 329,183 shares (a +3.1% increase). The purchase occurs against a backdrop of significant recent price weakness: the stock trades 44.2% below its 52-week high of $15.48 and has declined 14.5% over the past 30 days. The company's fundamentals remain solid with annual revenue growth of +6.0%, a P/E of 9.19, and quarterly revenue of $1.6B, suggesting the price decline has not been driven by fundamental deterioration. The timing of a CFO equity purchase during a period of sharp drawdown merits attention, though the transaction's ultimate significance will depend on whether this represents a standalone opportunistic entry or a broader pattern of insider accumulation.

Director Webb Robert Thomas buys 20,000 ARDT shares in 2 transactions for $339,600.00, doubling holdings to 40,275 shares.

Webb Robert Thomas, a Director at Ardent Health Partners, executed 2 separate purchases totaling 20,000 shares for $339,600.00 on November 8, 2024, at prices of $17.47 and $16.49 per share. This transaction increased his holdings by 98.6%, from 20,275 shares to 40,275 shares, representing a meaningful concentration of his stake in the company. The purchases occurred at $16.98 blended average, which is only 0.1% below the current price of $17.00 and sits 15.8% below the 52-week high of $20.19, indicating the acquisition was made during a period of relative weakness. With Ardent Health Partners operating at $1.4B in quarterly revenue and $2.4B market cap, the scale of this director-level accumulation warrants investor attention to whether this reflects confidence in near-term catalysts or operational momentum.